World Health Organization Issues Alert Over Severe Shortage of Weight-Loss Medications
Under a tenth of individuals that would benefit from obesity jabs including Wegovy can access them, caution the WHO as it publishes its initial advice on the medications.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for increased and just availability to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidance recognises that excess weight is a lifelong illness that can be treated with thorough and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are significant barriers to widespread access to the injections that can assist patients in reducing considerable weight, explains the agency.
Weight-Loss Drug Supply Crisis
Even under the current best projected outlook, the production of these medications might only reach approximately 100 million people – under 10% of the global need, as stated by the WHO.
The guideline encourages countries and companies to expand availability, through approaches including licensing agreements.
The intellectual property rights on the active ingredient – the primary ingredient of a leading brand – is due to expire in several countries in 2026.
How Weight-Loss Jabs Operate
GLP-1 drugs replicate a natural hormone to slow digestion, suppress the appetite and increase satiety so people reduce food intake.
Patients commonly begin shedding pounds in the initial weeks of commencing the weekly injections.
Studies points to people may see weight return a year later of discontinuing the drug, because their normal appetite return.
Being overweight or obese increases your likelihood for developing diseases, like diabetes, cardiovascular issues, stroke, and some cancers.
Obesity affects people in every country and was associated with millions of fatalities worldwide in 2024, as per the health agency.
